Clinical Evaluation of Relaxin in Ulcerative Ischemic Vascular or Collagen Diseases

Gb, Bradham; Jm, Stallworth; Le, Brailsford; Ba, Threatt

doi:10.1177/000331976201300904

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the following decades, research mainly continued to focus on the relaxin's functions in the female and also male reproductive system, with rare examples of studies that tended instead to identify for this hormone roles in different fields, such as wound healing, ulcerative ischemic vascular disease, therapy of pulmonary fibrosis, interaction with fibroblasts, and the action on collagen metabolism, where relaxin has demonstrated to exert a collagenolytic activity participating in the collagenases activation…”

Section: Relaxin's Historymentioning

confidence: 99%

Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein

Cernaro

Lacquaniti

Lupica

et al. 2013

Medicinal Research Reviews

View full text Add to dashboard Cite

Human relaxin-2 (hereafter simply defined as "relaxin") is a 6-kDa peptidic hormone best known for the physiological role played during pregnancy in the growth and differentiation of the reproductive tract and in the renal and systemic hemodynamic changes. This factor can also be involved in the pathophysiology of arterial hypertension and heart failure, in the molecular pathways of fibrosis and cancer, and in angiogenesis and bone remodeling. It belongs to the relaxin peptide family, whose members comprehensively exert numerous effects through interaction with different types of receptors, classified as relaxin family peptide (RXFP) receptors (RXFP1, RXFP2, RXFP3, RXFP4). Research looks toward the in-depth examination and complete understanding of relaxin in its various pleiotropic actions. The intent is to evaluate the likelihood of employing this substance for therapeutic purposes, for instance in diseases where a deficit could be part of the underlying pathophysiological mechanisms, also avoiding any adverse effect. Relaxin is already being considered as a promising drug, especially in acute heart failure. A careful study of the different RXFPs and their receptors and the comprehension of all biological activities of these hormones will probably provide new drugs with a potential wide range of therapeutic applications in the near future.

show abstract

Section: Relaxin's Historymentioning

confidence: 99%

Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein

Cernaro

Lacquaniti

Lupica

et al. 2013

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

Relaxin as a Drug

Schwabe

Büllesbach

1998

Relaxin and the Fine Structure of Proteins

View full text Add to dashboard Cite

Clinical Profile of Relaxin, a Possible New Drug for Human Use

Bani¹,

Yue²,

Bigazzi

2009

CDS

View full text Add to dashboard Cite

Relaxin (RLX) belongs to the relaxin hormone super-family, which in humans includes 3 RLX molecules and 4 insulin-like peptides. Of these, luteal RLX is the main circulating form in animals and man. RLX, formerly known for its effects on reproduction and pregnancy, has been demonstrated to act on numerous other targets, including the cardiovascular, central and peripheral nervous, respiratory, tegument, excretory and digestive systems. Most of these effects have been studied in animal models, but there is compelling evidence that RLX also acts in the human. Over time, RLX, as a crude or purified extract from corpora lutea or as a pure molecule produced by chemical synthesis or recombinant DNA technology, has been the object of clinical studies aimed at identifying its possible therapeutic fields of application. The availability of human recombinant RLX and the most recent achievements on its biological effects, especially on connective tissue remodelling and cardiovascular physiopathology, have sparkled a novel peak of interest of clinicians to the therapeutic potential of RLX. This review of the existing clinical studies with RLX is focused at its pharmacological and toxicological features, with the aim to support interest of clinicians and pharmaceutical companies to continue the pathway which may eventually succeed in translating RLX from the laboratory bench to the bedside.

show abstract

Clinical Evaluation of Relaxin in Ulcerative Ischemic Vascular or Collagen Diseases

Cited by 3 publications

References 2 publications

Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein

Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein

Relaxin as a Drug

Clinical Profile of Relaxin, a Possible New Drug for Human Use

Contact Info

Product

Resources

About